Advertisement

Topics

Nutlin-3, a p53-Mdm2 antagonist for nasopharyngeal carcinoma treatment

20:00 EDT 22 Aug 2017 | AAAS

(Bentham Science Publishers) Nasopharyngeal carcinoma (NPC) is a form of head and neck cancer that is highly prevalent among men in the populations of Southern China and Southeast Asia. This review will discuss the potential use of Nutlin-3 as a p53-activating drug and the future directions of its clinical research for NPC treatment.

Original Article: Nutlin-3, a p53-Mdm2 antagonist for nasopharyngeal carcinoma treatment

NEXT ARTICLE

More From BioPortfolio on "Nutlin-3, a p53-Mdm2 antagonist for nasopharyngeal carcinoma treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Searches Linking to this Story